<DOC>
	<DOCNO>NCT02953275</DOCNO>
	<brief_summary>The purpose study determine synergistic effect clinical benefit vedolizumab pentoxifylline management patient inflammatory bowel disease .</brief_summary>
	<brief_title>Synergistic Effect Vedolizumab Pentoxifylline</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Vedolizumab</mesh_term>
	<mesh_term>Pentoxifylline</mesh_term>
	<criteria>Patients active Crohn 's disease ( CD ) define blood lab value , stool marker , abnormal MR enterography imaging , colonoscopic finding Patients good candidate start standard dose vedolizumab Patients use offlabel investigational drug CD 8 week prior screen Patients meet washout period 8 week infliximab , 4 week certolizumab pegol , 2 week adalimumab history antiTNF exposure 8 week history exposure natalizumab Oral aminosalicylates allow study , provide dose stable least 2 week prior screen Oral corticosteroid allow provide dose prednisone ≤40 mg/day equivalent and/or budesonide ≤9mg/day stable least 2 week prior screen Patients able discontinue thiopurines ( azathioprine 6mercaptopurine ) methotrexate upon initiation vedolizumab Rectal therapy , narcotic , antidiarrheal , probiotic , antibiotic permit investigator discretion Contraindications history allergy PTX Known interaction PTX patient 's current medication Use offlabel investigational drug CD 8 week prior first VDZ infusion Pregnancy GFR &lt; 30 time 6 month prior first infusion VDZ Documented cirrhosis Age &lt; 18 &gt; 80 year old Contraindication colonoscopy 24 week study timepoint</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>